Silodosin as birth control pill for males
Not Applicable
Completed
- Registration Number
- CTRI/2017/09/009872
- Lead Sponsor
- TSS Hospital Sirsi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 63
Inclusion Criteria
Sexually active males opting for contraception are included
Exclusion Criteria
Those with sexual dysfunction, infertility, previous surgery, anomalies / instrumentation of their GU tract are excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of un intended pregnanciesTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method Adverse events related to silodosin intakeTimepoint: 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms, such as alpha-1A adrenergic receptor antagonism, mediate silodosin's reversible contraceptive effects in males?
How does silodosin 8 mg compare to standard male contraceptive methods like condoms or vasectomy in terms of efficacy and reversibility?
Are specific biomarkers like baseline testosterone levels or sperm parameters predictive of silodosin contraceptive response in clinical trials?
What adverse events were observed in the CTRI/2017/09/009872 trial, and how do they align with silodosin's known pharmacological profile in BPH treatment?
What are the potential advantages of silodosin over competitor non-hormonal male contraceptives like apalutamide or tamsulosin in terms of safety and efficacy?